


Bringing probiotics to life

# Product Portfolio



**We are a leading probiotics player inspired by developing probiotic solutions at the forefront of an expanding field. With science at the heart of everything we do, our products are supported by robust scientific documentation. We offer:**



1

Unique strains with characterised mechanisms of action



2

Scientifically documented, forward-looking probiotic solutions



3

Premium probiotic products adapted to your market

# Therapeutic areas we address

## Gastrointestinal health

### i3.1®

*P. acidilactici* KABP™ 021  
*L. plantarum* KABP™ 022  
*L. plantarum* KABP™ 023

### AB-DIGEST

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041  
*L. rhamnosus* GG

### AB-KOLICARE®

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041

## Oral health

### AB-DENTALAC®

*L. plantarum* KABP™ 051  
*L. brevis* KABP™ 052  
*P. acidilactici* KABP™ 053

### AB-IMPLALAC

*P. acidilactici* CECT 8904  
*P. pentosaceus* CECT 8905  
*P. acidilactici* CECT 8906

### DENTISANI

*S. dentisani* KABP™ 054

## Cardiometabolic health

### LIPIGO®

*Saccharomyces cerevisiae*  
postbiotic (BGCC extract)

### AB-LIFE®

*L. plantarum* KABP™ 011  
*L. plantarum* KABP™ 012  
*L. plantarum* KABP™ 013

### AB-DR7

*L. plantarum* DR7

### INNERIM®

*L. plantarum* KABP™ 031  
*L. plantarum* KABP™ 032

### MINDBIOME®

*L. plantarum* DR7

### AB21®

*L. plantarum* KABP™ 033  
*L. plantarum* KABP™ 022  
*L. plantarum* KABP™ 023  
*P. acidilactici* KABP™ 021

## Women's health

### GYNTIMA® CYSCARE

*L. plantarum* KABP™ 062  
*L. plantarum* KABP™ 063

### GYNTIMA® RESTORE

*L. plantarum* KABP™ 061

### GYNTIMA® MENOPAUSE

*L. plantarum* KABP™ 051  
*L. brevis* KABP™ 052  
*P. acidilactici* KABP™ 021

## Skin health

### AB-SAKEI 65®

*L. sakei* proBio 65

## Eye health

### AB-PROTEARS®

*L. sakei* proBio 65



# Our unique strains

Strain code		Mechanism of action
<i>Pediococcus acidilactici</i> KABP™ 021	CECT 7483	<ul style="list-style-type: none"> <li>→ Antagonistic activity <b>against FGIDs-related bacteria</b></li> <li>→ <b>Synthesis of SCFA</b> (acetate)</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 022	CECT 7484	<ul style="list-style-type: none"> <li>→ Enhancement of the intestinal barrier <b>via synthesis of poly-P granules</b></li> <li>→ <b>Reduction of inflammation</b> through the production of acetylcholine</li> <li>→ Antagonistic activity <b>against FGIDs-related pathogenic bacteria</b></li> <li>→ <b>Synthesis of SCFA</b> (acetate)</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 023	CECT 7485	<ul style="list-style-type: none"> <li>→ <b>Strong adhesive capacity to the intestinal epithelium</b></li> <li>→ <b>Modulation of the innate and adaptive immune responses</b></li> <li>→ Synthesis of p40 and p75 proteins, that <b>protect the epithelial barrier, enhance intestinal cells' function and promote the production of IgA</b></li> <li>→ <b>Antagonistic activity against gastrointestinal tract pathogens</b></li> </ul>
<i>Lacticaseibacillus rhamnosus</i> GG	ATCC 531033	<ul style="list-style-type: none"> <li>→ <b>Strong adhesive capacity to the intestinal epithelium</b></li> <li>→ <b>Modulation of the innate and adaptive immune responses</b></li> <li>→ Synthesis of p40 and p75 proteins, that <b>protect the epithelial barrier, enhance intestinal cells' function and promote the production of IgA</b></li> <li>→ <b>Antagonistic activity against gastrointestinal tract pathogens</b></li> </ul>
<i>Bifidobacterium longum</i> KABP™ 042	CECT 7894	<ul style="list-style-type: none"> <li>→ <b>Antagonistic activity against colic-related pathogenic bacteria</b></li> <li>→ <b>Digestion of HMOs</b>, supporting a healthy gut colonisation</li> <li>→ <b>Homofermentative metabolism</b> (no CO<sub>2</sub> production)</li> <li>→ <b>Synergic protection of intestinal epithelial barrier (tight junctions)</b></li> </ul>
<i>Pediococcus pentosaceus</i> KABP™ 041	CECT 8330	<ul style="list-style-type: none"> <li>→ <b>Induction of anti-inflammatory molecules (IL-10)</b></li> <li>→ <b>Homofermentative metabolism</b> (no CO<sub>2</sub> production)</li> <li>→ <b>Antagonistic activity against colic-related pathogenic bacteria</b></li> <li>→ <b>Synergic protection of intestinal epithelial barrier (tight junctions)</b></li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 051	CECT 7481	<ul style="list-style-type: none"> <li>→ <b>Effective colonization of the oral cavity</b>, thanks to high resistance to oral conditions, good adherence to oral tissues and high ability to form aggregates</li> </ul>
<i>Levilactobacillus brevis</i> KABP™ 052	CECT 7480	<ul style="list-style-type: none"> <li>→ Inhibition of <b>oral pathogens associated with gingivitis</b> and periodontitis</li> </ul>
<i>Pediococcus acidilactici</i> KABP™ 053	CECT 8633	<ul style="list-style-type: none"> <li>→ Modulation of mucosal immunity reducing the synthesis of several inflammatory cytokines (IL-1β, IL-8)</li> </ul>

# Our unique strains

Strain code		Mechanism of action
<i>Streptococcus dentisani</i> KABP™ 054	CECT 7746	<ul style="list-style-type: none"> <li>→ Inhibition of 20 different bacteria species implicated in oral disease</li> <li>→ <b>Regulation of oral pH</b>, balancing the oral environment after a meal</li> <li>→ Synthesis of anti-inflammatory cytokine IL-10</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 011	CECT 7527	<ul style="list-style-type: none"> <li>→ Modification of the enterohepatic cycle through a <b>high BSH activity</b></li> <li>→ Capacity to <b>capture intestinal cholesterol</b>, promoting its excretion</li> <li>→ <b>Reduction of apolipoprotein (Apo) B100 and ApoB48</b> in plasma, two accurate markers of cardiovascular risk</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 012	CECT 7528	
<i>Lactiplantibacillus plantarum</i> KABP™ 013	CECT 7529	
<i>Saccharomyces cerevisiae</i> postbiotic	BGCC extract	<ul style="list-style-type: none"> <li>→ Specific <b>binding to saturated fats</b>, limiting its absorption through the intestinal wall</li> </ul>
<i>Lactobacillus plantarum</i> DR7®	CECT 7481	<ul style="list-style-type: none"> <li>→ Regulation of neuroactive molecules, with effects on the <b>serotonin</b>-kynurenine pathway and <b>dopamine</b>-norepinephrine pathway</li> <li>→ Gut microbiota modulation, increasing <b>bacteria diversity</b></li> <li>→ Reduction of stress-associated molecules (cortisol) plasma levels.</li> <li>→ Improvement of anti-inflammatory (IL-10) versus pro-inflammatory (TNF-<math>\alpha</math>, IFN-<math>\gamma</math>) signals</li> <li>→ <b>Antioxidative properties</b></li> <li>→ Antagonistic activity against pathogens linked with URTIs</li> </ul>
<i>Levilactobacillus brevis</i> KABP™ 052	CECT 7480	<ul style="list-style-type: none"> <li>→ Production of GABA, dopamine and acetylcholine modulating the <b>gut-brain and gut-liver axis</b></li> <li>→ Estrogen-deconjugation activity, helping to <b>slow down the estrogen decline</b></li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 031	CECT 7315	<ul style="list-style-type: none"> <li>→ Synthesis of acetate linked with an <b>increase in IgA</b> (increased immune protection) and induction of T-cells</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 032	CECT 7316	<ul style="list-style-type: none"> <li>→ Modulation of several anti and proinflammatory cytokines</li> <li>→ Reduction of TGF-<math>\beta</math>1, improving the immune response</li> </ul>

# Our unique strains

Strain code		Mechanism of action
<i>Lactiplantibacillus plantarum</i> KABP™ 033	CECT 30292	<ul style="list-style-type: none"> <li>→ High plnG gene activity, <b>boosting the adaptative immune response</b> by direct cross-talk with dendritic cells and macrophages</li> <li>→ Increased production of specific antibodies</li> </ul>
<i>Latilactobacillus sakei</i> proBio 65	KCTC 10755BP	<ul style="list-style-type: none"> <li>→ Stimulation of <b>regulatory lymphocytes</b>, linked with an increased production of several cytokines (IL-10, IL-12, IL-17, IFN-<math>\gamma</math>)</li> <li>→ Reduction of chemokines associated with <b>allergic responses and inflammatory processes</b>, at systemic and local levels</li> <li>→ Antimicrobial activity against <b>bacteria associated with atopic dermatitis</b></li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 062	CECT 8675	<ul style="list-style-type: none"> <li>→ Antimicrobial effect against <b>uropathogenic bacteria</b></li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 063	CECT 8677	<ul style="list-style-type: none"> <li>→ Biofilm formation and acidification capacity, preventing overgrowth of undesirable bacteria in the urinary tract</li> </ul>
<i>Lactiplantibacillus plantarum</i> KABP™ 061	CECT 7504	<ul style="list-style-type: none"> <li>→ Antagonistic activity against pathogenic bacteria causing infections such as bacterial vaginosis, <b>balancing vaginal microbiota</b></li> <li>→ High adhesion capacity to the vaginal epithelium</li> <li>→ Acidification of the vagina preventing overgrowth of undesirable bacteria</li> <li>→ Antimicrobial effect against <b>Candida</b> spp.</li> </ul>

**Our probiotic solutions**

# Gastrointestinal health

# i3.1®

*P. acidilactici* KABP™ 021  
*L. plantarum* KABP™ 022  
*L. plantarum* KABP™ 023  
 3 billion CFU/dose



## Indications

- Irritable bowel syndrome (IBS)
- Stress-related digestive disorders
- Food intolerances (lactose and fructose)
- For easy digestions and good intestinal transit

## Finished formulas

- Probiotic alone
- Probiotic + Vitamin D



CAPSULES



STICKS



DROPS

## Clinical evidence

- Lorenzo-Zúñiga V, et al. i3.1, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. *World J. Gastroenterol.* 20, 8709–8716 (2014).
- Barraza-Ortiz DA, et al. Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study. *Dig. Dis.* (2020).
- Cano-Contreras A, et al. Efficacy of probiotic i3.1 symptomatic improvement in patients with lactose intolerance. *J Clin. Gastroenterol.* (2020).
- Lorén V, et al. Comparative effect of the i3.1 probiotic formula in two animal models of colitis. *Probiotics Antimicrob. Proteins.* 9, 71–80 (2017).
- Perez M, et al. Derived postbiotics of a multi-strain probiotic formula clinically validated for the treatment of Irritable bowel syndrome. *FASEB J.* 34, 1–1 (2020).
- Sato, T. et al. A probiotic blend improves defecation, mental health, and productivity in healthy Japanese volunteers under stressful situations. *Heliyon* 8, (2022).
- Jouët, P, et al. Probiotics plus vitamin D in irritable bowel syndrome: a prospective multicentric non-interventional study. *Minerva gastroenterology* (2024)

# AB-DIGEST

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041  
*L. rhamnosus* GG  
 6 billion CFU/dose

## Indications

- Antibiotic-associated diarrhea in adults and children
- Constipation
- Gut microbiota restoration
- Immune support

## Finished formulas

- Probiotic + Inulin + Fructooligosaccharides (FOS) + Zinc
- Probiotic + Psyllum



SHOTS



STICKS



DROPS

## Clinical evidence\*

- Hempel S, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA.* 9, 1959–69 (2012).
- Szajewska H, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. *Aliment. Pharmacol. Ther.* 42, 1149–57 (2014).
- Astó E, et al. Equivalence of a novel *Lactobacillus rhamnosus* isolate to the reference ATCC53103 strain. Poster presented at SEPyP congress (2018).
- Astó E et al. Probiotic Properties of *Bifidobacterium longum* KABP™ 042 and *Pediococcus pentosaceus* KABP™ 041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol* 12, (2022).
- Espadaler-Mazo J et al. *Bifidobacterium longum* KABP042 utilizes Human Milk Oligosaccharides to boost production of polyphosphate granules, strengthening intestinal barrier. Poster presented at ESPGHAN congress (2023).



Our probiotic solutions

# Pediatric health

# AB-KOLICARE®

*B. longum* KABP™ 042  
*P. pentosaceus* KABP™ 041  
1 billion CFU/dose



## Indications

- Infant colic
- Functional gastrointestinal disorders (FGIDs) in babies and toddlers
- For a healthy gut microbiota development during the first 1000 days

## Finished formulas

- Probiotic alone
- Probiotic + HMOs
- Probiotic + Vitamin D



DROPS

## Clinical evidence

- Chen K. et al. Infantile colic treated with *Bifidobacterium longum* CECT7894 and *Pediococcus pentosaceus* CECT8330: A randomized, double-blind, placebo-controlled trial. *Frontiers in Pediatrics* 0, 939 (2021).
- Asto E et al. Probiotic Properties of *Bifidobacterium longum* KABP™ 042 and *Pediococcus pentosaceus* KABP™ 041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol* 12, (2022).
- Santas JM, et al. *Pediococcus pentosaceus* CECT 8330 and *Bifidobacterium longum* CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. *Int J Pharm Bio Sci.* 6, 458-466 (2015).
- Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. *Int. J. pharma Bio Sci.* 8, 281-288 (2017).
- Dong F et al. *Pediococcus pentosaceus* CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice. *Journal of Translational Medicine* 20, 1-16 (2022).

## Clinical evidence (continued)

- Espadaler-mazo et al. *Bifidobacterium longum* KAPB042 utilizes human milk oligosaccharides to boost production of polyphosphate granules, strengthening intestinal barrier. *JPGN*, volume 76, Supplement 1, June 2023. Poster accepted at ESPGHAN congress (2023).
- Alcántara C, Perez M, Huedo P, et al. Study of the biosynthesis and functionality of polyphosphate in *Bifidobacterium longum* KAPB042. *Sci Rep.* 2023;13(1):11076.
- Valverde-Molina J et al. Comparative efficacy of probiotic mixture *Bifidobacterium longum* KAPB042 plus *Pediococcus pentosaceus* KABP041 vs. *Limosilactobacillus reuteri* DSM17938 for infant colic management: a randomized clinical trial. Poster accepted at ESPGHAN congress (2024).

Our probiotic solutions

# Oral health

# AB-DENTALAC®

*L. plantarum* KABP™ 051  
*L. brevis* KABP™ 052  
*P. acidilactici* KABP™ 053  
 1 billion CFU/dose

# AB-IMPLALAC

*P. acidilactici* CECT 8904  
*P. pentosaceus* CECT 8905  
*P. acidilactici* CECT 8906  
 1 billion CFU/dose

## Indications

- Gingivitis and periodontitis
- Faster recovery after oral surgery
- Bad breath
- Oral microbiota balance

## Indications

- Peri-implantitis
- Oral microbiota balance

## Finished formulas

- Probiotic alone
- Probiotic + Vitamin D



TABLETS



VIALS



GUMS

## Finished formulas

- Probiotic alone
- Probiotic + Vitamin D



TABLETS



VIALS

## Clinical evidence

- Nart J et al. Oral colonization by *Levilactobacillus brevis* KABP 052 and *Lactiplantibacillus plantarum* KABP 051: A randomized, double-blinded, placebo-controlled trial (pilot study). *J Clin Exp Dent* 13, 433–439 (2021).
- Montero E, et al. Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: A randomized controlled clinical trial. *J. Clin. Periodontol.* 44, 708–716 (2017).
- Ferrés-Amat E, et al. Probiotics diminish the post-operative pain following mandibular third molar extraction: A randomised double-blind controlled trial (pilot study). *Benef. Microbes* 11, 631–639 (2020).
- Calabuig RP, et al. Oral probiotic reduces pain after third molar extraction procedure. Poster presented at SEPyP congress (2019).
- Bosch M, et al. Isolation and characterization of probiotic strains for improving oral health. *Arch Oral Biol.* 57, 539–349 (2012).

## Clinical evidence

- Clinical trial on-going: evaluation of the improvement of peri-implantitis state in implants treated with probiotics.

# DENTISANI

*S. dentisani* KABP™ 054  
2.5 billion CFU/dose



## Indications

- Dental caries
- Bad breath
- Maintains a clean, plaque-free mouth

## Finished formulas

- Probiotic alone
- Heat-inactivated strain (postbiotic)



ORAL GEL



TOOTHPASTE

## Clinical evidence

1. Ferrer, M. D. et al. Topic Application of the Probiotic *Streptococcus dentisani* Improves Clinical and Microbiological Parameters Associated With Oral Health. *Front Cell Infect Microbiol* 10, 465 (2020).
2. Ferrer, M. D. et al. A pilot study to assess oral colonization and pH buffering by the probiotic *Streptococcus dentisani* under different dosing regimes. *Odontology* 2019 108:2 108, 180–187 (2019).
3. Llana, C. et al. Antimicrobial efficacy of the supernatant of *Streptococcus dentisani* against microorganisms implicated in root canal infections. *J Oral Sci* 61, 184–194 (2019).
4. Esteban-Fernández, A. et al. Inhibition of oral pathogens adhesion to human gingival fibroblasts by wine polyphenols alone and in combination with an oral probiotic. *J Agric Food Chem* 66, 2071–2082 (2018).
5. Camelo-Castillo, A., et al. *Streptococcus dentisani* sp. nov., a novel member of the mitis group. *Int J Syst Evol Microbiol* 64, 60–65 (2014).

## Clinical evidence (continued)

6. López-López, A. et al. Health-associated niche inhabitants as oral probiotics: The case of *Streptococcus dentisani*. *Front Microbiol* 8, 379 (2017).
7. Esteban-Fernández, A. et al. In vitro beneficial effects of *Streptococcus dentisani* as potential oral probiotic for periodontal diseases. *J Periodontol* 90, 1346–1355 (2019).
8. López-Santacruz, H. D. et al. *Streptococcus dentisani* is a common inhabitant of the oral microbiota worldwide and is found at higher levels in caries-free individuals. *International Microbiology* 2021 24:4 24, 619–629 (2021).
9. Ferrer, M. D. et al. Evaluation of clinical, biochemical and microbiological markers related to dental caries. *Int J Environ Res Public Health* 18, (2021).
10. Conrads, G. et al. Isolation and bacteriocin-related typing of *Streptococcus dentisani*. *Front Cell Infect Microbiol* 9, 110 (2019).



# Cardiometabolic health

## AB-LIFE®

*L. plantarum* KABP™ 011  
*L. plantarum* KABP™ 012  
*L. plantarum* KABP™ 013  
 1.2 billion CFU/dose



### Indications

- Hypercholesterolemia
- Hypertriglyceridemia
- Maintains a healthy blood lipid profile



### Finished formulas

- Probiotic alone
- Probiotic + Vitamin B1
- Probiotic + Omega 3 (ALA)
- Probiotic + Monacolin K



CAPSULES



STICKS



DROPS

### Clinical evidence

1. Fuentes, M. C., Lajo, T., Carrión, J. M. & Cuñé, J. Cholesterol-lowering efficacy of *Lactobacillus plantarum* CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. *Br. J. Nutr.* 109, 1866–1872 (2013)
2. Espadaler J, et al. Demographic and clinical characteristics influencing the effects of a cholesterol-lowering probiotic. *Ann. Nutr. Metab.* 74, 1–31 (2019).
3. Bosch M, et al. *Lactobacillus plantarum* CECT 7527, 7528 and 7529: Probiotic candidates to reduce cholesterol levels. *J. Sci. Food Agric.* 94, 803–809 (2014).
4. Kim DH, et al. Effect of mixture of *Lactobacillus plantarum* CECT 7527, 7528, and 7529 on obesity and lipid metabolism in rats fed a high-fat diet. *J. Korean Soc. Food Sci. Nutr.* 43, 1484–1490 (2014).
5. Mukerji P, et al. Safety evaluation of AB-LIFE®: Antibiotic resistance and 90-day repeated-dose study in rats. *Food Chem. Toxicol.* 92, 117–128 (2016).
6. Guerrero-Bonmatty, R et al. A Combination of *Lactoplantibacillus plantarum* strains CECT7527, CECT7528, and CECT7529 plus monacolin K reduces blood cholesterol: Results from a randomized, double-blind, placebo-controlled Study. *Nutrients* 2021, Vol. 13, Page 1206 13, 1206 (2021).
7. Padro T, de Santisteban V, Huedo P, et al. *Lactiplantibacillus plantarum* strains KABP011, KABP012 and KABP013 modulate bile acids and cholesterol metabolism in humans. *Cardiovasc Res.* Published online March 25, 2024.
8. Kerlikowsky, F., Müller, M., Greupner, T. et al. Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of *Lactobacillus plantarum* Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study. *Probiotics & Antimicro. Prot.* (2023).

## LIPIGO®

*Saccharomyces cerevisiae* postbiotic  
 (BGCC extract)  
 3000 mg/dose



### Indications

- Prevents rebound effect
- Safe weight loss
- Overweight and type I obesity

### Finished formulas

- Postbiotic alone



STICKS

### Clinical evidence

1. Santas J, et al. Effect of a polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) in body weight loss: randomised, double-blind, placebo-controlled clinical trial in overweight and obese adults. *J Sci Food Agric.* 97, 4250–7 (2017).
2. Valero-Pérez, M. et al. Regular consumption of Lipigo® promotes the reduction of body weight and improves the rebound effect of obese people undergo a comprehensive weight loss program. *Nutrients* 2020, Vol. 12, Page 1960 12, 1960 (2020).
3. Santas J, et al. Polysaccharide-rich hydrolysate from *Saccharomyces cerevisiae* (LipiGO®) increases fatty acid and neutral sterol excretion in guinea pigs fed with hypercholesterolemic diets. *Eur J Lipid Sci Technol.* 119, 17001–04 (2017).

**Immune health**

# AB-DR7

*L. plantarum* DR7  
1 billion CFU/dose

# INNERIM®

*L. plantarum* KABP™ 031  
*L. plantarum* KABP™ 032  
1 billion CFU/dose



## Indications

- Upper respiratory tract infections (URTIs)
- Respiratory health
- Immunity support

## Indications

- Immunity support
- Prevention of immunity ageing
- Sports performance
- Increase of power and energy levels

## Finished formulas

- Probiotic alone
- Probiotic + Vitamin D
- Probiotic + Vitamin C
- Probiotic + Zinc



CAPSULES



STICKS



DROPS

## Finished formulas

- Probiotic + Vitamin B9 + B6 + B12 + C + A + Zinc + Selenium
- Probiotic + Vitamin B9 + B6 + B12 + C + A + Zinc + Selenium + CoQ10



CAPSULES



STICKS



DROPS

## Clinical evidence

- Chong HX, et al. *Lactobacillus plantarum* DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study. *J. Dairy Sci.* 102, 4783–4797 (2019).
- Altadill T, et al. Does *Lactoplantibacillus plantarum* DR7 reduce days of upper respiratory tract infections and fever? A post-hoc analysis of a randomized, placebo-controlled trial. *FASEB Journal* (2021).
- Baud D, et al. Using probiotics to flatten the curve of coronavirus disease COVID-2019. *Pandemic. Front. Public Heal.* 8, (2020).
- Low LC, et al. Effects of potential probiotic strains on the fecal microbiota and metabolites of d-galactose-induced aging rats fed with high-fat diet. *Probiotics Antimicrob. Proteins.* 12, 545–562 (2020).

## Clinical evidence

- Mañé J, et al. A mixture of *Lactobacillus plantarum* CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. *Nutr. Hosp.* 26, 228–235 (2011).
- Bosch M, et al. El consumo del probiótico *Lactobacillus plantarum* CECT 7315/7316 mejora el estado de salud general en personas de edad avanzada. *Nutr. Hosp.* 26, 642–645 (2011).
- Bosch M, et al. *Lactobacillus plantarum* CECT 7315 and CECT 7316 stimulate immunoglobulin production after influenza vaccination in elderly. *Nutr. Hosp.* 27, 504–509 (2012).
- Vilahir G, et al. *Lactobacillus plantarum* CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response. *Eur. J. Nutr.* 54, 1161–1171 (2015).
- Bosch M, et al. Probiotic properties of *Lactobacillus plantarum* CECT 7315 and CECT 7316 isolated from faeces of healthy children. *Lett. Appl. Microbiol.* 54, 240–246 (2012).

# AB21®

- L. plantarum* KABP™ 033
- L. plantarum* KABP™ 022
- L. plantarum* KABP™ 023
- P. acidilactici* KABP™ 021

2 billion CFU/dose



## Indications

- Viral respiratory infections in adults and children
- To boost adaptive immunity (specific antibody production)
- Mild to moderate COVID-19 symptoms

## Finished formulas

- Probiotic alone
- Probiotic + Vitamin D
- Probiotic + Zinc



CAPSULES



STICKS



DROPS

## Clinical evidence

1. Gutiérrez-Castrellón, P. et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. *Gut Microbes* 14, (2022).
2. Gutierrez-Castrellon, P., et al. Probiotic effect on SARS-CoV2 immunity is associated to type-I interferons: A post-hoc analysis of a randomized, placebo-controlled trial. *The FASEB Journal* 36, (2022).
3. Espadaler Mazo et al. Eficacia y seguridad del probiótico AB21 en niños con infecciones respiratorias comunes de origen vírico. *Anales de Microbiota, Probióticos y Prebióticos*. Vol. 5 · Nº 1, p. 195 (2024).
4. Altadill, T et al. Probiotic blend of *L. plantarum* and *P. acidilactici* (AB21) stimulates type-I interferon response in phagocytes with the participation of the IRF7 transcription factor, possibly involving both MyD88-dependent and independent mechanisms. *Journal of Biological Chemistry* 300, 105827 (2024).

For more info visit:

[ab21probiotic.com](https://ab21probiotic.com)





Our probiotic solutions

# Cognitive health

# MINDBIOME®

*L. plantarum* DR7  
1 billion CFU/dose



## Indications

- Stress and anxiety
- Emotional wellbeing
- Memory and cognition
- To sleep and rest better

## Finished formulas

- Probiotic alone
- Probiotic + Magnesium
- Probiotic + Melatonin
- Probiotic + Ashwagandha + GABA + Vitamin B6



CAPSULES



STICKS

## Clinical evidence

1. Chong HX, et al. *Lactobacillus plantarum* DR7 alleviates stress and anxiety in adults: A randomised, double-blind, placebo-controlled study. *Benef. Microbes* 10, 355–373 (2019).
2. Liu G, et al. *Lactobacillus plantarum* DR7 modulated bowel movement and gut microbiota associated with dopamine and serotonin pathways in stressed adults. *Int. J. Mol. Sci.* 21, 4608 (2020).
3. Lew LC, et al. Effects of potential probiotic strains on the fecal microbiota and Metabolites of d-Galactose-Induced Aging Rats Fed with High-Fat Diet. *Probiotics Antimicrob. Proteins* 12, 545–562 (2020).

Our probiotic solutions

# Skin health

# AB-SAKEI 65®

*L. sakei* proBio 65  
5 billion CFU/dose

## Indications

- Atopic dermatitis
- Skin irritation, redness and discomfort
- Promotes skin hydration and elasticity to prevent wrinkles

## Finished formulas

- Probiotic alone
- Probiotic + Zinc
- Probiotic + Niacin + Vitamin C
- Postbiotic alone (lysate)



CAPSULES



STICKS



CREAM

## Clinical evidence

1. Woo SI, et al. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann. Allergy, Asthma Immunol.* 104, 343–348 (2010).
2. Park SB, et al. Effect of emollients containing vegetable-derived lactobacillus in the treatment of atopic dermatitis symptoms: Split-body clinical trial. *Ann. Dermatol.* 26, 150–155 (2014).
3. Rather IA, et al. Oral administration of live and dead cells of *Lactobacillus sakei* proBio65 alleviated atopic dermatitis in children and adolescents: a randomized, double-blind, and placebo-controlled Study. *Probiotics Antimicrob. Proteins* (2020).
4. Lim J, et al. Immune-modulating characteristics of *Lactobacillus sakei* proBio65 isolated from Kimchi. *Korean J. Microbiol. Biotechnol.* 39, 313–316 (2011).
5. Kim JY, et al. Atopic dermatitis-mitigating effects of new *Lactobacillus* strain, *Lactobacillus sakei* probio 65 isolated from Kimchi. *J. Appl. Microbiol.* 115, 517–526 (2013).

Our probiotic solutions

# Women's health



# GYNTIMA® CYSCARE

*L. plantarum* KABP™ 062  
*L. plantarum* KABP™ 063  
1 billion CFU/dose

## Indications

- Urinary tract infections (UTIs)
- Urogenital microbiota balance



## Finished formulas

- Probiotic alone
- Probiotic + Cranberry extract + Vitamin C



CAPSULES

## Clinical evidence

1. Simón E, et al. Screening of *Lactobacilli* strains of human origin candidates for the prevention of urinary tract infections. *Ann. Nutr. Metab.* 74, 1–31 (2019).
2. Effective use of a *Lactiplantibacillus plantarum* mixture with cranberry and vitamin C in the reduction of recurrence of urinary tract infections in women: a randomized controlled trial. *Manuscript under preparation.*
3. Padayatty SJ, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *J Am Coll Nutr.* 22, 18–35 (2003)
4. Wang CH, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med.* 172, 988–96 (2012).
5. Salo J, et al. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized controlled trial. *Clin Infect Dis.* 54, 340–6 (2012).

# GYNTIMA® RESTORE

*L. plantarum* KABP™ 061

## Indications

- Vaginal candidiasis
- Vaginosis

## Finished formulas

- Postbiotic (heat-inactivated strain) + Lactic acid
- Probiotic alone



VAGINAL  
TABLETS

## Clinical evidence

1. Palacios S, et al. Is it possible to prevent recurrent vulvovaginitis? Role of *Lactobacillus plantarum* 11001 (CECT7504). *Eur J Clin Microbiol. Infect. Dis.* 35, 1701–8 (2016).
2. Bonachera-Sierra MA, et al. Heat-inactivated *Lactiplantibacillus plantarum* KABP 061 exerts antipathogenic activity against causative agents of vulvovaginal candidiasis. Poster presented at IHMC Congress, Kobe, Japan (2022).

# GYNTIMA<sup>®</sup> MENOPAUSE

*L. plantarum* KABP™ 051  
*L. brevis* KABP™ 052  
*P. acidilactici* KABP™ 021  
1 billion CFU/dose

new!

## Indications

- Estrogen level decline
- Menopause-related symptoms

## Finished formulas

- Probiotic alone
- Probiotic + Vitamin D + Vitamin B9 + Vitamin B6



CAPSULES



STICKS

## Clinical evidence

1. Honda et al. Supplementation with a probiotic blend increases serum estrogen levels in the peri/post-menopausal women. Poster presented at PROBIOTA congress (2024). *Publication submitted.*

Eye health

# AB-PROTEARS®

*L. sakei* proBio 65  
1 billion CFU/dose

## Indications

- Dry eye or ocular irritation
- Allergies and inflammation of the eye surface

## Finished formulas

- Lysate (postbiotic) + Hypromellose



EYE DROPS

## Clinical evidence

1. Iorio, R. et al. *Lactobacillus sakei* pro-bio65 reduces  $\text{tnf-}\alpha$  expression and upregulates gsh content and antioxidant enzymatic activities in human conjunctival cells. *Transl Vis Sci Technol* 10, (2021).
2. Heydari M, et al. The Effect of Ophthalmic and Systemic Formulations of *Latilactobacillus sakei* on Clinical and Immunological Outcomes of Patients With Dry Eye Disease: A Factorial, Randomized, Placebo-controlled, and Triple-masking Clinical Trial. *Probiotics Antimicrob Proteins*. 2023 May 31. Epub ahead of print. PMID: 37256485.

# Our available formats

# Our available formats

## CAPSULES



- 5 capsules
- 15 capsules
- 30 capsules
- bulk

## MICROENCAPSULATED CAPSULES



- 5 capsules
- 15 capsules
- 30 capsules
- bulk

Probiotics microencapsulated with PROBS® technology, to ensure stability when mixed with specific ingredients like Omega 3 oil or Cranberry extract

## STICKS



- 2 sticks
- 20 sticks
- 30 sticks
- 42 sticks
- 90 sticks
- bulk

## SHOTS



- 5 shots
- 7 shots
- 10 shots
- bulk

## BLUE OR INLINE DROPPER



- 3ml shots
- 8ml shots
- 10ml shots
- bulk

# Our available formats

## EYE DROPPER



- 3ml dropper
- 8ml dropper

## ORAL GUMS



- 8 tablets

## ORAL TABLETS



- 5 tablets
- 10 tablets
- 15 tablets
- 30 tablets
- 60 tablets
- bulk

## VIAL



- 3ml
- 8ml shots
- 10ml shots
- bulk

## VAGINAL TABLETS



- 7 tablets + 1 applicator
- 7 tablets no applicator
- 7 tablets blister in bulk
- 7 tablets + 7 applicator

# Quality standards



Patented products



Clinically-proven  
and safe



Organic strains,  
natural origin



Allergen-free



Qualified Presumption of  
Safety status (EFSA)



Not modified  
genetically



Generally Recognised as Safe (FDA) and/or  
Natural Product Number (Health Canada)



**Our global footprint gives us a unique view of the ever changing probiotic landscape enabling us to offer regulatory support in not only supplements, and functional foods but also OTC and medical applications to meet the needs of consumers worldwide.**



[www.ab-biotics.com](http://www.ab-biotics.com)  
[hello@ab-biotics.com](mailto:hello@ab-biotics.com)